Abstract
Pharmacologic inhibition of indoleamine 2,3-dioxygenase (IDO) activity during murine pregnancy results in maternal T-cell-mediated rejection of allogeneic but not syngeneic conceptuses. Increased risk of allogeneic pregnancy failure induced by exposure to IDO inhibitor is strongly correlated with maternal C3 deposition at the maternal-fetal interface. Here we review evidence that cells expressing IDO contribute to immunosuppression by inhibiting T-cell responses to tumor antigens and tissue allografts, as well as fetal tissues.
MeSH terms
-
Animals
-
Enzyme Inhibitors / pharmacology
-
Female
-
Humans
-
Immune Tolerance* / drug effects
-
Indoleamine-Pyrrole 2,3,-Dioxygenase
-
Inflammation / enzymology
-
Inflammation / immunology
-
Maternal-Fetal Exchange / drug effects
-
Maternal-Fetal Exchange / immunology*
-
Mice
-
Neoplasms / enzymology
-
Neoplasms / immunology
-
Pregnancy
-
T-Lymphocytes / immunology
-
Transplantation Immunology
-
Tryptophan Oxygenase / antagonists & inhibitors
-
Tryptophan Oxygenase / immunology*
Substances
-
Enzyme Inhibitors
-
Indoleamine-Pyrrole 2,3,-Dioxygenase
-
Tryptophan Oxygenase